Stay updated with breaking news from Transcode Therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Get Rating) CEO Robert Michael Dudley bought 19,000 shares of the stock in a transaction on Friday, June 9th. The shares were acquired at an average cost of $2.76 per share, for a total transaction of $52,440.00. Following the acquisition, the chief executive officer now directly owns 912,114 shares in […]
Vodafone Group was the biggest company on a market cap basis to set a new 52-week low. • The smallest company by market cap to set a new 52-week low was…
TransCode Therapeutics, Inc. (RNAZ) shares are gaining more than 7 percent on Tuesday morning trade after reaching a year-to-date low on Monday. The company had announced a 1-for-20 reverse stock split, effective May 22.
Clinical Stage Platform Delivery Company Overcoming Intractable Problems in Oncology and Beyond ... | May 15, 2023
Terns Pharmaceuticals (NASDAQ:TERN – Get Rating) and TransCode Therapeutics (NASDAQ:RNAZ – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, analyst recommendations, earnings and valuation. Insider and Institutional Ownership 15.9% of TransCode Therapeutics shares […]